Host |
Rabbit |
Klon |
SP154 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hepatocellular Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human AFP |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Zytomed Systems |
SP154 |
1 ml |
Concentrate |
RUO |
501-4544 |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Fetal Liver |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Diagnostic Biosystems |
C3 |
1 ml |
Concentrate |
CE/IVD |
MOB129 |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Fetal Liver |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Diagnostic Biosystems |
C3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB129-01 |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Fetal Liver |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Diagnostic Biosystems |
C3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB129-05 |
-
|
Host |
Mouse |
Klon |
C3 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Fetal Liver |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
AFP (Alpha-Fetoprotein)
|
Diagnostic Biosystems |
C3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM057 |
-
|
Host |
Mouse |
Klon |
7E1 |
Format |
Concentrate |
Methode |
F, WB, EL, IP |
Isotyp |
IgG1 |
Verdünnung |
Purified human articulate cartilage Aggregan |
Aggrecan
|
Zytomed Systems |
7E1 |
0.2 mg (1 mg/ml) |
Concentrate |
RUO |
601-0091C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Serum |
Methode |
F, EL, WB |
Isotyp |
Rabbit IgG |
Verdünnung |
Bovine albumin |
Albumin (Bovine) (BSA)
|
Zytomed Systems |
polyclonal |
1 ml |
Serum |
RUO |
601-0351 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Liver |
Verdünnung |
1:50 - 1:1000 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Albumin (HSA)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP046 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Liver |
Verdünnung |
1:50 - 1:1000 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Albumin (HSA)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP046-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Liver |
Verdünnung |
1:50 - 1:1000 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Albumin (HSA)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP046-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, EL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the amino acids 1-3 of the native molecule conjugated to bovine serum albumin |
Aldosterone
|
Zytomed Systems |
polyclonal |
1 ml |
Purified |
RUO |
601-0145 |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Biocare Medical |
5A4 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3041A |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Biocare Medical |
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3041B |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm and nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Biocare Medical |
5A4 |
6 ml |
Ready-to-use |
CE/IVD |
API3041AA |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic Lymphoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Diagnostic Biosystems |
5A4 |
1 ml |
Concentrate |
CE/IVD |
MOB416 |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic Lymphoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Diagnostic Biosystems |
5A4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB416-01 |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic Lymphoma |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Diagnostic Biosystems |
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB416-05 |
-
|
Host |
Mouse |
Klon |
5A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus (dot-like) |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Zytomed Systems |
5A4 |
0.5 ml |
Concentrate |
CE/IVD |
MSK096-05 |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm, Nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Origene |
1A4 |
0.1 ml |
Concentrate |
RUO |
R0001MA01-MA |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm, Nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Origene |
1A4 |
0.5 ml |
Concentrate |
RUO |
R0001MA05-MA |
-
|
Host |
Rabbit |
Klon |
ZR305 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma or lung |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human ALK-protein fragment around aa 1058 - 1620 |
Lokalisation |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Zeta Corporation |
ZR305 |
1 ml |
Concentrate |
CE/IVD |
Z2534RL |
-
|
Host |
Rabbit |
Klon |
ZR305 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma or lung |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Human ALK-protein fragment around aa 1058 - 1620 |
Lokalisation |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Zeta Corporation |
ZR305 |
7 ml |
Ready-to-use |
CE/IVD |
Z2534RP |
-
|
Host |
Rabbit |
Klon |
ZR305 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma or lung |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human ALK-protein fragment around aa 1058 - 1620 |
Lokalisation |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Zeta Corporation |
ZR305 |
0.5 ml |
Concentrate |
CE/IVD |
Z2534RS |
-
|
Host |
Rabbit |
Klon |
ZR305 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Anaplastic large cell lymphoma or lung |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Human ALK-protein fragment around aa 1058 - 1620 |
Lokalisation |
Cytoplasm and nucleus |
ALK/p80 (Anaplastic Lymphoma Kinase)
|
Zeta Corporation |
ZR305 |
0.1 ml |
Concentrate |
CE/IVD |
Z2534RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR021 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP048 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP048-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Alpha-1-Antitrypsin (AAT)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP048-05 |
-
|
Host |
Mouse |
Klon |
INN-hFSH 100 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human FSH |
alpha2-HCG (Human Chorionic Gonadotropin)
|
Zytomed Systems |
INN-hFSH 100 |
500 µg |
Purified |
RUO |
601-0178 |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4 + ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1a/k |
Verdünnung |
Human AMACR (P504S) and p63 polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63
|
Zeta Corporation |
13H4 + ZM70 |
1.0 ml |
Concentrate |
CE/IVD |
Z2008MRL |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4 + ZM70 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
- |
Isotyp |
IgG, IgG1a/k |
Verdünnung |
Human AMACR (P504S) and p63 polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63
|
Zeta Corporation |
13H4 + ZM70 |
7 ml |
Ready-to-use |
CE/IVD |
Z2008MRP |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4 + ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1a/k |
Verdünnung |
Human AMACR (P504S) and p63 polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63
|
Zeta Corporation |
13H4 + ZM70 |
0.5 ml |
Concentrate |
CE/IVD |
Z2008MRS |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4 + ZM70 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate carcinoma. |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1a/k |
Verdünnung |
Human AMACR (P504S) and p63 polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63
|
Zeta Corporation |
13H4 + ZM70 |
0.1 ml |
Concentrate |
CE/IVD |
Z2008MRT |
-
|
Host |
Rabbit + Mouse |
Klon |
13H4 + ZM70 + 34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1 + IgG2a |
Verdünnung |
Human AMACR (P504S) , p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63 + HMW CK Cocktail
|
Zeta Corporation |
13H4 + ZM70 + 34βE12 |
1 ml |
Concentrate |
CE/IVD |
Z2015MRL |
-
|
Host |
Rabbit + Mouse |
Klon |
13H4 + ZM70 + 34βE12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
- |
Isotyp |
IgG, IgG1 + IgG2a |
Verdünnung |
Human AMACR (P504S) , p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63 + HMW CK Cocktail
|
Zeta Corporation |
13H4 + ZM70 + 34βE12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2015MRP |
-
|
Host |
Rabbit + Mouse |
Klon |
13H4 + ZM70 + 34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1 + IgG2a |
Verdünnung |
Human AMACR (P504S) , p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63 + HMW CK Cocktail
|
Zeta Corporation |
13H4 + ZM70 + 34βE12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2015MRS |
-
|
Host |
Rabbit + Mouse |
Klon |
13H4 + ZM70 + 34βE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG1 + IgG2a |
Verdünnung |
Human AMACR (P504S) , p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR + p63 + HMW CK Cocktail
|
Zeta Corporation |
13H4 + ZM70 + 34βE12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2015MRT |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
1.0 ml |
Concentrate |
RUO |
Z2005MRL-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
- |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
7 ml |
Ready-to-use |
RUO |
Z2005MRP-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
0.5 ml |
Concentrate |
RUO |
Z2005MRS-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a/k |
Lokalisation |
Cytoplasm and nucleus |
AMACR+p63
|
Zeta Corporation |
13H4+4A4 |
0.1 ml |
Concentrate |
RUO |
Z2005MRT-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
1ml |
Concentrate |
RUO |
Z2017MRL-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
- |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
7 ml |
Ready-to-use |
RUO |
Z2017MRP-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
0.5 ml |
Concentrate |
RUO |
Z2017MRS-R |
-
|
Host |
Rabbit and Mouse |
Klon |
13H4+4A4+34bE12 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Prostate intraepithelial neoplasia (PIN) |
Verdünnung |
1:50 |
Isotyp |
IgG, IgG2a + IgG1 |
Verdünnung |
Human AMACR (P504S), p63, and CKHMW (34βE12) polypeptides |
Lokalisation |
Cytoplasm and Nucleus |
AMACR+p63+HMW CK
|
Zeta Corporation |
13H4+4A4+34bE12 |
0.1 ml |
Concentrate |
RUO |
Z2017MRT-R |
-
|
Host |
Sheep |
Klon |
polyclonal |
Format |
Purified |
Methode |
WB, EL |
Isotyp |
Sheep IgG |
Verdünnung |
Native pancreatic amylase |
Amylase (Pancreas)
|
Zytomed Systems |
polyclonal |
1 ml |
Purified |
RUO |
601-0204 |
-
|
Host |
Mouse |
Klon |
R10/99 |
Format |
TCS |
Methode |
F, P |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
CATQRLANFLV cuopled to tuberculin |
Amylin (Peptide)
|
Zytomed Systems |
R10/99 |
2 ml |
TCS |
RUO |
601-0206 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP123 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP123-01 |
-
|
Host |
Rabbit |
Klon |
Polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Brain |
Verdünnung |
1:50 - 1:100 |
Lokalisation |
Cytoplasm, extracellular |
Amyloid
|
Diagnostic Biosystems |
Polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP123-05 |
-
|